FOSTER CITY, CA--(Marketwire - November 13, 2007) - SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported results for the third quarter ended September 30, 2007. For the third quarter 2007, product revenues from the sale of ZADAXIN® (thymalfasin), SciClone’s lead product, increased by 14% to $9,421,000, compared with revenues of $8,270,000 for the third quarter 2006. For the nine months ended September 30, 2007, product revenues increased by 13% to $27,020,000, compared with product revenues of $23,969,000 for the same period of 2006. The increase in product revenues for the third quarter and nine months ended September 30, 2007 is primarily attributable to an increase in the quantity of ZADAXIN sold in China, which accounted for approximately 92% of total ZADAXIN sales for the quarter.
